Chonluten

Chonluten (EDG, also referenced as Tripeptide T-34) is a synthetic tripeptide developed by Prof. Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, positioned as the bronchopulmonary (lung and bronchial)-tissue-focused member of the institute's "cytogen" line of single-sequence synthetic bioregulator peptides, alongside Vilon (thymus), Livagen (liver), Cardiogen (heart), and Epithalon (pineal gland), all also built on this site.

Chemically, Chonluten is a three-residue peptide: molecular formula C11H17N3O8, molecular weight approximately 319.27 g/mol, CAS number 75007-24-8, PubChem CID 194641. Chonluten is one of two related bronchopulmonary Khavinson peptides described in the literature — the other, a tetrapeptide called Bronchogen (Ala-Glu-Asp-Leu, AEDL), is a distinct compound not built on this site, and researchers should be careful not to conflate the two, since they are separate sequences studied together in some of the same review literature but are chemically and individually distinct.

At Verified Peptides, we think Chonluten's evidence base sits in a moderate position relative to other Khavinson-associated peptides in this catalog: better documented than Cardiogen (for which we located no dedicated indexed study at all) but still substantially reliant on the compound's own developing institute, with one notable exception detailed below involving an internationally co-authored study.

The broader biological rationale for a bronchopulmonary-focused bioregulator peptide connects to a real and independently established area of respiratory biology: lung tissue is subject to substantial oxidative and inflammatory stress over a lifetime from inhaled particulates, pathogens, and normal metabolic byproducts, and bronchial epithelial cell turnover and repair capacity are understood to decline with age, contributing to increased vulnerability to chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD) and chronic bronchitis in older populations. This general biological backdrop is the legitimate scientific context in which Chonluten's proposed lung-tissue-supportive effects are framed, independent of whether the specific tripeptide itself has been independently shown to meaningfully influence that process.

At Verified Peptides, we want to walk through Chonluten's evidence base directly. A 2020 review by Khavinson and colleagues, "Peptides: Prospects for Use in the Treatment of COVID-19" (Molecules, PMID 32987757), describes oral administration of Chonluten (EDG) as effective for bronchopulmonary pathology including chronic obstructive pulmonary disease and chronic bronchitis with an asthmatic component, reporting an increase in a physical performance index and normalization of functional state, and stating that it "enhanced the effectiveness of standard therapy" in chronic bronchitis patients. We want to be direct about what this citation actually is: a review article authored by the compound's own developing institute, describing clinical observations that are not presented with randomization, blinding, placebo control, or the kind of detailed methodology that would let an independent reader assess the claim's reliability. It is a real, indexed, international-journal publication — a step above unindexed vendor claims — but it is not equivalent to an independently verified clinical trial.

The more methodologically reassuring citation is the 2022 International Journal of Molecular Sciences study (PMID 35408963) described above, which directly tested Chonluten in human THP-1 cells under defined laboratory conditions with an independent (Italian university) lead institution, finding TNF-production inhibition under LPS stimulation. This gives Chonluten a genuine, specific, collaboratively-verified in vitro finding, which is more than we could establish for some other Khavinson cytogens in this same build batch.

We are not aware of any randomized, controlled human clinical trial of Chonluten, and no FDA, EMA, or other Western regulatory body has evaluated or approved it for any indication. At Verified Peptides, we sell research-grade Chonluten exclusively for laboratory research, and we encourage researchers to weigh the 2022 cell-culture finding, which we consider genuinely useful evidence, more heavily than the institute-authored clinical-observation claims from the 2020 review, which carry considerably less independent verification.

Chonluten is frequently discussed alongside a related but distinct compound, Bronchogen (Ala-Glu-Asp-Leu, AEDL), a tetrapeptide also developed within Khavinson's bronchopulmonary research line. The two are often mentioned together in the same review literature — including the 2020 COVID-19 peptides review — as complementary bronchopulmonary bioregulators, but they are separate sequences with individually distinct research histories, and researchers should not treat findings about one as automatically applicable to the other.

The alternate designation "Tripeptide T-34" reflects an internal numbering convention used within the Khavinson bioregulator catalog for tracking specific sequences across the institute's decades of peptide characterization work, similar in spirit to how Cardiogen is sometimes marketed as "CardioCytogen."

The 2022 International Journal of Molecular Sciences study that tested Chonluten (as "P5") alongside Vilon (as "P2") and three other Khavinson peptides in the same THP-1 cell-culture system is notable as one of relatively few instances in this catalog's research literature where multiple organ-specific cytogens were evaluated under identical experimental conditions in the same publication, allowing at least some direct, controlled comparison between compounds that are otherwise usually described only in separate, non-comparable studies.

The specific gene-expression targets attributed to Chonluten in institute-authored literature — c-Fos, HSP70, SOD, COX-2, and TNF-α — are all genuinely well-established markers in mainstream stress-response and inflammation biology; the mainstream significance of these markers is independently established even though the specific claim that Chonluten modulates all of them as described has not been independently verified outside Khavinson-affiliated research.

c-Fos, specifically, is a well-known immediate-early gene whose expression is induced rapidly and transiently in response to a wide range of cellular stimuli, and is used broadly across neuroscience and cell biology as a general marker of cellular activation rather than a marker specific to any one tissue or pathway. HSP70 is similarly a broadly conserved cellular stress-response protein induced under heat, oxidative, and other stress conditions across essentially all human tissue types, not a lung-specific marker. Citing effects on these genes is scientifically meaningful only in the context of the specific experimental data supporting it, since both genes are activated by an enormous range of stimuli unrelated to any particular peptide.

At Verified Peptides, we require independent third-party HPLC purity testing and mass spectrometry identity confirmation for every batch of research-grade Chonluten we offer, with a Certificate of Analysis (COA) available for each lot. As a three-residue peptide, Chonluten is straightforward to synthesize to high purity using standard solid-phase peptide synthesis methods.

We source exclusively from manufacturers operating under Good Manufacturing Practice (GMP)-aligned quality systems, and every lot is independently verified rather than accepted solely on a supplier's internal documentation. Researchers should always request and review the specific COA for the lot they receive, confirming purity percentage and molecular identity before use in any experimental protocol.

Lyophilized Chonluten is stable when stored at -20°C, protected from light and moisture, and researchers can generally expect the unreconstituted peptide to maintain integrity over an extended period under these conditions. At Verified Peptides, we ship lyophilized peptide with appropriate cold-chain packaging to preserve stability in transit.

Once reconstituted with bacteriostatic water or another appropriate sterile diluent, Chonluten solution should be stored refrigerated at 2–8°C and used within the timeframe indicated on the product's documentation. As with other short peptides in this catalog, reconstituted solutions are generally less stable than the lyophilized form and more susceptible to degradation and microbial contamination with repeated freeze-thaw cycling.

Researchers should avoid repeated freeze-thaw cycles of reconstituted material and should follow the specific storage guidance provided with each lot's documentation to preserve sample validity for research use.